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ORIGINAL ARTICLE
The impact of HIV and antiretroviral therapy on
TB risk in children: a systematic review and
meta-analysis
P J Dodd,1 A J Prendergast,2,3 C Beecroft,1 B Kampmann,4,5 J A Seddon4
ABSTRACT
Background Children (<15 years) are vulnerable to TB
disease following infection, but no systematic review or
meta-analysis has quantiﬁed the effects of HIV-related
immunosuppression or antiretroviral therapy (ART) on
their TB incidence.
Objectives Determine the impact of HIV infection and
ART on risk of incident TB disease in children.
Methods We searched MEDLINE and Embase for
studies measuring HIV prevalence in paediatric TB cases
(‘TB cohorts’) and paediatric HIV cohorts reporting TB
incidence (‘HIV cohorts’). Study quality was assessed
using the Newcastle-Ottawa tool. TB cohorts with
controls were meta-analysed to determine the incidence
rate ratio (IRR) for TB given HIV. HIV cohort data were
meta-analysed to estimate the trend in log-IRR versus
CD4%, relative incidence by immunological stage and
ART-associated protection from TB.
Results 42 TB cohorts and 22 HIV cohorts were
included. In the eight TB cohorts with controls, the IRR
for TB was 7.9 (95% CI 4.5 to 13.7). HIV-infected
children exhibited a reduction in IRR of 0.94 (95%
credible interval: 0.83–1.07) per percentage point
increase in CD4%. TB incidence was 5.0 (95% CI 4.0 to
6.0) times higher in children with severe compared with
non-signiﬁcant immunosuppression. TB incidence was
lower in HIV-infected children on ART (HR: 0.30; 95%
CI 0.21 to 0.39). Following initiation of ART, TB
incidence declined rapidly over 12 months towards a HR
of 0.10 (95% CI 0.04 to 0.25).
Conclusions HIV is a potent risk factor for paediatric
TB, and ART is strongly protective. In HIV-infected
children, early diagnosis and ART initiation reduces TB
risk.
Trial registration number CRD42014014276.
INTRODUCTION
Children are at high risk of progression to TB
disease following infection with Mycobacterium
tuberculosis, particularly children in the ﬁrst
2 years of life, who often develop non-pulmonary
forms of TB.1 The variety of presentation, difﬁculty
in obtaining samples for laboratory testing and pau-
cibacillary nature of disease mean that conﬁrming a
TB diagnosis in children can be challenging. This
adds to difﬁculties in understanding the natural
history and epidemiology of disease. Recent indir-
ect approaches to burden estimation have used
mathematical modelling of exposure and disease
progression risks to predict paediatric TB
incidence.2 WHO estimated that in 2014, 1 million
children developed TB globally.3
Although programmes to prevent
mother-to-child transmission (PMTCT) of HIV
have reduced new cases of vertically infected
infants, coverage is incomplete; in 2013, an esti-
mated 199 000 (170 000–230 000) children were
newly infected with HIV.4 Children experience
more rapid HIV disease progression than adults,
making them highly susceptible to opportunistic
infections.5 Antiretroviral therapy (ART) can
restore immune function and has enormously
reduced morbidity and mortality among
HIV-infected children. In 2015, WHO guidelines
were revised, recommending all HIV-infected chil-
dren should initiate ART, irrespective of clinical
disease stage or degree of immunosuppression.6
However, ART coverage among children lags
behind adults, with only one-third of eligible chil-
dren currently on ART compared with two-thirds
of adults.4
In adults, HIV is a known potent risk factor for
developing TB, with incident rate ratios (IRR) >5
when averaged across all levels of immunodeﬁ-
ciency.7 Evidence synthesis suggests an exponential
increase in the IRR with decrease in CD4 T-cell
counts.8 9 The effect of ART in reducing TB risk in
adults living with HIV infection is well described.10
This quantitative understanding of the effects of
HIV and ART on TB progression has been widely
used by modellers, for example, in predicting the
Key messages
What is the key question?
▸ What effects do HIV infection and antiretroviral
therapy (ART) have on TB risk in children?
What is the bottom line?
▸ HIV infection increases the incidence of TB in
children by a factor of around 8, increasing
with degree of immunosuppression; ART
reduces TB risk by around 70%, with protection
continuing to increase over 1–2 years.
Why read on?
▸ TB incidence in HIV-infected children is very
high, but no systematic review has quantiﬁed
the effects of HIV or ART on TB risk in children.
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impact of HIV interventions on TB incidence.9 11 12 In contrast
to adults, the impact of HIV infection and ART on TB progres-
sion in children is poorly quantiﬁed; no systematic reviews have
been performed to evaluate this relationship. In the context of
revised WHO treatment recommendations, our objective was
therefore to systematically review the paediatric HIV/TB litera-
ture to quantify the effect of HIV and ART on TB risk in
children.
METHODS
This systematic review is reported in accordance with the
Preferred Reporting Items for Systematic Review and
Meta-Analyses statement13 (see online supplementary material).
A protocol was registered with PROSPERO (identiﬁcation
number: CRD42014014276) in October 2014.
Cohort deﬁnitions
For all studies, the exposure/intervention was HIV infection,
with or without ART. We sought studies that either: (i) reported
HIV prevalence in children with TB (‘TB cohorts’) or (ii)
reported TB disease incidence in cohorts of children with HIV
(‘HIV cohorts’). For TB cohorts, the outcome was HIV preva-
lence, and the comparator was HIV prevalence in control
groups of children without TB. For HIV cohorts, the outcome
was TB incidence, and the comparison was between subgroups
of the same cohort with different levels of immune suppression,
or ARTexposure (all HIV-infected).
Search strategy, selection criteria, data extraction
To be eligible, a study had to present empirical data on more
than ﬁve cases of TB in children (aged <15 years). Studies were
excluded if they were not generally representative of paediatric
TB cases in that population at that time, for example, studies
that only addressed one form of TB; that only comprised hospi-
talised TB cases; studies explicitly focused on migrant popula-
tions or autopsy studies. If the same cohort was published more
than once, or individuals were described in more than one
cohort, studies/children were only included once. Where explicit
use of isoniazid preventive therapy (IPT) was stated, children
receiving IPT were excluded. TB cohorts were excluded if the
coverage of HIV testing was below 70% among TB cases. HIV
cohorts were excluded if data were not reported that could be
interpreted as an incidence (ie, number of events and
person-time).
MEDLINE and Embase were systematically searched without
language, publication or date restrictions using terms designed
to capture children and TB and (HIV or ART) on 20 December
2014 (see online supplementary material for full search). A
combination of MeSH and EMTREE headings were used with
free-text terms to enhance the sensitivity of the search. We
further searched the Cochrane Controlled Trials Register and
AIDSinfo for relevant studies. All references in review articles
found by our database search were included. All citations listed
in Google Scholar of the ﬁve most cited review articles found by
our database search were screened. One additional study in
press at the time of our systematic review was brought to our
attention after presenting draft results.14 Two investigators (PJD
and JAS) independently assessed titles and abstracts for inclu-
sion. Full texts were independently assessed for inclusion and
study type by PJD and JAS with disagreements resolved by dis-
cussion. Two investigators extracted the data for TB cohorts in
tandem; PJD extracted the data for HIV cohorts with 25% of
data checked by JAS.
For both study designs, the following were recorded: ﬁrst
author, publication year, study years, study country, number of
TB cases, age range, number of male children. For TB cohorts,
if local TB-free controls were reported in the study, the HIV
prevalence among control children (numerator and denomin-
ator) was extracted. Other data extracted from the TB cohorts
included: the coverage of HIV testing, the numerator and
denominator of HIV prevalence in TB cases and the UNAIDS
paediatric HIV estimate for corresponding country-year (if avail-
able; mid-point and uncertainty range). For HIV cohorts, the
following were recorded: TB incidence (with uncertainty range),
ART coverage at enrolment, estimate of protective effect of ART
against TB (if present) and TB incidence in any ART-related
or immune-related stratum (with uncertainty range).
Co-trimoxazole use was recorded where described. TB incidence
by age band was extracted if present. Some studies recorded
immune status using the WHO immunological classiﬁcation6
(not-signiﬁcant, mild, advanced and severe immunosuppres-
sion), whereas others used alternative CD4% or CD4 count cat-
egories, which differed between studies. Mid-points and CIs
(assumed Poisson exact) were used to infer event numbers and
person-time when aggregation was necessary. Some studies
excluded incident TB within the ﬁrst few months on ART,
stating that they sought to exclude immune reconstitution
inﬂammatory syndrome reactions and only determine true TB
incidence.
Quality of individual studies was assessed using an adapted
Newcastle-Ottawa quality assessment tool.15 The version for
case-control studies was used for TB cohorts; the version for
cohort studies for HIV cohorts. For HIV cohorts, the quality
for each study as input to each meta-analysis was assessed separ-
ately (see online supplementary material pp. 18–21) and
reported as low/moderate/high quality (depending on whether
few/some/most criteria were met) on domains of selection, com-
parability and either outcome (for cohort studies) or exposure
(for case-control studies).
Statistical analyses
For TB cohorts, we undertook a random-effects meta-analysis
of the OR for HIV prevalence given TB among those studies
reporting HIV prevalence in controls. This OR can be inter-
preted as an IRR for developing TB disease if HIV positive7 (see
online supplementary material p. 7). We produced funnel plots
to assess evidence of publication bias.
For TB cohorts where UNAIDS estimates of national HIV
prevalence in the age group aged <15 years were available for
the same year and country as the study, we undertook a
Bayesian meta-analysis using both the UNAIDS data and control
data. This analysis modelled the relationship between UNAIDS
HIV prevalence and HIV prevalence in study controls from
studies where both were available, and used this relationship to
predict individual study ORs where controls were not available.
For comparison, a Bayesian version of the meta-analysis of
studies with controls was conducted (see online supplementary
material pp. 8–11).
For HIV cohorts reporting TB incidence by immune stage, we
undertook a random-effects meta-analysis of the IRR for each
stratum relative to the ‘not-signiﬁcant’ WHO immune stage. For
HIV cohorts reporting incidence by >1 CD4% category (using
the mid-point of the CD4% category in which the incidence
was reported), or an analysis of the relation between CD4% and
IRR for TB, we undertook a Bayesian meta-analysis to estimate
the gradient of logarithmic IRR with respect to CD4% (see
online supplementary material pp. 13–15). We averaged the IRR
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implied by this point estimate over CD4% between 0% and
50% to compare with our IRR from the TB cohort analysis. For
HIV cohorts reporting an estimate of the protection against TB
from ART as a HR, we performed a random-effects
meta-analysis. For HIV cohorts reporting TB incidence by >1
category of time-since-ART-initiation, we ﬁtted a non-linear
mixed-effects model to estimate the temporal dependence of
ART protection, using the mid-point of the time window in
which the incidence was reported to model incidence (see
online supplementary material pp. 15–16).
Bayesian techniques were employed where greater ﬂexibility
was required over standard software implementations to use all
the data. All statistical analyses were undertaken using R statis-
tical software (R Core Team. R: A language and environment
for statistical computing. R Foundation for Statistical
Computing, Vienna, Austria. URL http://www.R-project.org);
random-effects meta-analysis was performed using the rma
command in the metafor package implementing the restricted
maximum-likelihood estimator.16
RESULTS
Search results
The systematic review process is presented in ﬁgure 1. Of the
311 full-text articles screened, 65 were included in this review.
The most common reasons for exclusion were HIV test coverage
<70% for TB cohorts (n=46) and TB incidence not reported
for HIV cohorts (n=22). Of the 65 included studies, 42 were
classiﬁed as TB cohorts (see table 1), 22 were classiﬁed as HIV
cohorts (see table 2) and 1 study included both a TB and HIV
cohort.17 Thirty-one of the 42 TB cohorts (74%) and 17 of the
22 HIV cohorts (77%) were from sub-Saharan Africa.
Of the TB cohorts, 8 included HIV prevalence in controls
without TB and could be used in the random-effects
meta-analysis; 35 had relevant UNAIDS estimates and could be
included in the Bayesian meta-analysis, including all 8 studies
with controls.
Of the HIV cohorts, 7 could be included in the meta-analysis
of CD4% inﬂuence, 3 could be included in the analysis of the
inﬂuence of immunological staging, 10 were included in the
analysis of time on ART and 6 were included in the pooled esti-
mate of ART efﬁcacy against TB. Only three HIV cohorts
reported co-trimoxazole use.14 67 80
HIV prevalence in TB cohorts ranged between 5% and 94%
(see online supplementary material p. 5). TB incidence in HIV
cohorts ranged from 0.3 to 25.3 per 100 person-years (see
online supplementary material p. 6). Insufﬁcient data were avail-
able in either group of cohorts to stratify results by age.
Quality assessment
TB cohorts were of low and moderate quality for our analysis
(table 1). Studies without controls could not be classed higher
than moderate quality on selection and low quality on exposure.
Controls were often drawn from clinic populations in the same
context. In around half of studies, TB was deﬁned only by a
decision to treat.
HIV cohorts were typically of low quality for our analyses
(table 2). Most studies were clinic-based and not necessarily
community-representative; prevalent TB was not always ruled
out at baseline; there were often shortcomings in follow-up or
case deﬁnitions for TB.
Meta-analyses for TB cohorts
The random-effects meta-analysis of TB cohorts for the odds of
having HIV in TB cases included eight case-control studies
(ﬁgure 2). In total, 1215 TB cases and 1232 non-TB controls
were included. The pooled estimate for the OR was 7.9 (95%
CI 4.5 to 13.7), and the I-squared heterogeneity statistic (I2) was
69.8% (see ﬁgure 2). A funnel plot corresponding to this ana-
lysis is presented in online supplementary material p. 8.
The Bayesian meta-analysis included 35 studies (including all
8 with controls) and produced a pooled estimate of the OR for
HIV among children with TB of 7.0 (95% credible interval
(CrI): 5.7–8.5), see ﬁgure 3. This analysis also found the paedi-
atric HIV prevalence in controls to be substantially higher than
national UNAIDS estimates of HIV prevalence in the age group
aged <15 years, with an OR of 7.3 (95% CrI: 5.9 to 8.8). For
studies that lacked explicit control groups (indicated in red in
ﬁgure 3), this analysis also predicted what the ORs would have
been for HIV prevalence in TB cases versus HIV prevalence in a
putative control group of comparable children without TB. The
pooled estimates of effect for the analyses with and without the
UNAIDS data were similar (see online supplementary material
p. 11).
Meta-analyses for HIV cohorts
For HIV cohorts, the random-effects meta-analysis of TB inci-
dence in children with severe compared with non-signiﬁcant
immunosuppression according to the WHO categorisation gave
an IRR of 5.0 (95% CI 4.0 to 6.0) with I2=87.1% (see
ﬁgure 4). The Bayesian meta-analysis of the gradient of the loga-
rithmic IRR with respect to CD4% yielded a pooled estimate of
−0.063 (95% CrI: −0.188 to +0.063), corresponding to a
reduction in IRR of 0.94 (95% CrI: 0.83 to 1.07) per one
percentage-point increase in CD4% (see ﬁgure 5). This point
estimate implies a mean IRR of 7.1 over CD4% ranging
between 0% and 50%. The random-effects meta-analysis of pro-
tection from ART yielded a pooled HR estimate of 0.30 (95%
CI 0.21 to 0.39) with I2=79% (see ﬁgure 6).
The non-linear mixed-effects regression for the protection
from ART by time-since-initiation estimated a rapid initial
decline in incidence over the ﬁrst year, reaching a plateau as
protection from ART fully establishes over around 2 years at a
pooled asymptotic HR of 0.10 (95% CI 0.04 to 0.25), giving a
mean HR over the ﬁrst 30 months on ART of approximately
0.25 (see ﬁgure 7).
DISCUSSION
In this systematic review, we identiﬁed cohorts of children with
TB and cohorts of children with HIV. We observed a high but
variable prevalence of HIV infection in the TB cohorts, and a
very high TB incidence in the HIV cohorts. Accounting for
background risk of TB, we found, as in adults, HIV was import-
ant risk factor for TB and that TB risk increases with immuno-
suppression. ART was strongly protective against TB, but took
2 years for full potential of protection against TB to be realised.
In adults, IRRs for TB given HIV around six have been esti-
mated for populations with generalised HIV epidemics,7 corre-
sponding to most newly diagnosed adult TB cases having HIV
infection. Our IRR for children is comparable, but lower HIV
prevalence is seen in children with TB due to a lower overall
paediatric HIV prevalence. In adults, meta-analyses of cohorts
of HIV patients suggest exponentially increasing IRR for TB
with declining CD4 cell count,9 and current CD4 cell counts on
ART strongly predict TB incidence.81 A systematic review and
meta-analysis of the protective effect of ART against TB found a
HR of 0.35 (0.28–0.44) across all baseline CD4 cell counts,10
comparable to our result for children. Long-term follow-up of
adults on ART suggests 4–5 years for protection against TB to
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become fully established.82 Our analysis suggests that protection
against TB in children on ART establishes more rapidly (1–
2 years), consistent with faster CD4 reconstitution among chil-
dren83 compared with adults.84 85
Our ﬁndings have implications for patient care, guidelines,
TB programmes and mathematical modelling. For clinicians, TB
risk with HIV and ART informs patient treatment and appropri-
ate family counselling. For TB programme ofﬁcers, understand-
ing risks informs resource allocation, and service conﬁguration
for HIV testing and treatment. These ﬁndings can inform
evidence-based guideline development; timely given the recent
revision of the WHO ART guidelines advocating universal treat-
ment for children with HIV, irrespective of clinical and immuno-
logical stage. Finally, these data inform models of burden
estimates and for evaluating the impact of interventions, in rela-
tion to HIV and ART.
Our review has limitations. Although our search strategy was
comprehensive, studies were excluded if not representative of
children with TB in that context. The cohorts identiﬁed were
generally of low quality for our analyses, the most common
shortcomings being around population representativeness and
TB case-deﬁnitions. The majority of studies were from
sub-Saharan Africa, where 90% of all HIV-infected children
live, and the ﬁndings may not generalise to other regions. The
studies spanned a long time period, and may not be representa-
tive of the current era. Statistical heterogeneity was high for
summary statistics from both TB cohorts and especially HIV
cohorts, reﬂecting diverse study settings and dates, and unre-
ported clinical and methodological heterogeneity. However,
measures of heterogeneity were comparable with those from
similar studies.86 There were a number of limitations of our
meta-analyses of TB cohort data. Controls were often not from
the general population. This may partially explain the differ-
ences between HIV prevalence in study controls and UNAIDS
paediatric HIV prevalence estimates. However, UNAIDS reports
country-level estimates for children aged <15 years, which are
not likely to reﬂect the HIV prevalence in younger children
local to these studies. Difﬁculties in diagnosing TB in children
with HIV may have led to differential detection of cases by HIV
status, affecting the IRR from case-control TB cohorts.
Moreover, estimates of the increased risk of TB progression will
be confounded by higher exposure due to sharing households
with HIV-infected parents, themselves at increased risk of TB.
This makes it difﬁcult to differentiate the direct biological
impact of HIV from indirect effects. Implicitly, our analyses
assume the same relationship between HIV, ART and TB holds
regardless of population TB or HIV prevalence, which may not
be the case across the very wide range of prevalences in the
studies included.
A number of limitations apply to our meta-analyses of HIV
data. CD4% categories were disparately reported, and we used
category mid-points for analyses of CD4% and time-on-ART.
Figure 1 Preferred Reporting Items
for Systematic Review and
Meta-Analyses ﬂow chart for
systematic review (*one study included
both a TB and HIV cohort17).
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Figure 2 Forest plot for meta-analysis of HIV risk in children aged <15 years with prevalent TB—studies with controls (I2=69.8%). RE, random
effects.
Figure 3 Forest plot for Bayesian
meta-analysis of HIV risk in children
aged <15 years with prevalent TB.
Where studies lacked their own
controls, UNAIDS national HIV
prevalence data were used to model
HIV prevalence in controls based on
those studies with both controls and
UNAIDS estimates (red). Meta-analyses
for studies with controls only are
shown in blue; meta-analyses for
studies using UNAIDS estimates of
paediatric HIV prevalence are shown in
red.
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Many studies allowed for unmasking of prevalent TB at ART
initiation by excluding a certain period after initiation from
comparisons, but this varied between studies. However, exclud-
ing all children diagnosed with TB soon after initiating ART
may underestimate early incident TB in children who are still
highly immunosuppressed. Only three HIV cohorts reported
co-trimoxazole use,14 67 80 but as guidelines have varied over
time and by setting, co-trimoxazole use may have been under-
reported. Confounding by indication was not considered in esti-
mates of ART protection (except for Edmonds et al70), and
choice of covariates varied between studies. Our direct
meta-analysis of the protective effect of ART was not able to
include how long children had been on ART, and will average
over the different distribution of treatment durations between
studies.
We were not able to analyse age effects on TB, as data were
seldom reported with multiple age stratiﬁcations. Our analysis
of protection by time-on-ART may be confounded by age.
Young children have particularly high TB progression risk, in
part due to immature cell-mediated immune responses.1 The
impact of age on efﬁcacy of ART is also complex, as early ART
initiation, at a better baseline immune status, leads to better
immune reconstitution (although adherence can be challenging
at the youngest ages due to a paucity of palatable
formulations).83 87 88 The studies in our review were conducted
over years when ART treatment guidelines, availability and for-
mulations were evolving. The relevance of our ﬁndings to
current universal treatment recommendations needs careful con-
sideration; individual patient data meta-analysis would be highly
informative on the impact of host characteristics on risk of TB,
in particular the age of the child and age at which ART was
initiated. As children are started on ART at higher CD4 values,
the protective beneﬁt of ARTagainst TB may be lower.
Despite these limitations, internal consistency between results
from different analyses increases the conﬁdence in our conclu-
sions. Our IRR from TB cohorts is comparable with the estimate
of ‘severe’ compared with ‘not signiﬁcant’ immune staging,
recognising that HIV may confer an increased risk of TB even
before immunosuppression is clinically evident. The mean IRR
over a range of CD4% between 0% and 50% was 7.1 using the
risk gradient point-estimate from our CD4 analysis—close to
our IRR estimate for all HIV from TB cohorts. The mean pro-
tection against TB over the ﬁrst 30 months on ARTwas 0.25—
comparable to our meta-analysis of estimates of protection
(although these analyses ultimately stem from the same data).
The decline in TB rates by time-on-ART occurred on a similar
timescale to the analysis presented by Li et al,73 although to a
lower ﬁnal value. Comparing our HIV and ART risk results
Figure 4 Relative TB incidence in children aged <15 years with HIV by WHO immunological staging (I2=87.1%).
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suggests that children commencing ART are at higher risk of TB
than HIV-uninfected children initially, but our results are too
uncertain to specify whether long-term TB risks ART return to
those of an HIV-uninfected child. For adults, TB risks estab-
lished on long-term ART remain elevated over those of
HIV-uninfected individuals.82
It is important to place ART in the context of other public
health interventions. Our results suggest early diagnosis of
infants and young children with HIV, followed by immediate
ART, will reduce the pool of highly susceptible children and
consequent progression to TB disease, providing further
impetus to scale-up coverage among paediatric ART
Figure 5 Forest plot for
meta-analysis of relation between
incidence rate ratio for TB incidence
and CD4% in children aged <15 years.
Figure 6 Forest plot of protection on
antiretroviral therapy against TB
incidence in children <15 years with
HIV infection (I2=79.0%). RE, random
effects.
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programmes. High HIV prevalence in the TB cohorts and high
TB incidence in the HIV cohorts suggest that all children diag-
nosed with TB should be tested for HIV infection and all chil-
dren with HIV should be regularly screened for TB disease.
Scale-up of PMTCT will lead to fewer children becoming
infected with HIV and is likely to be one of the most effective
public health strategies to reduce paediatric HIV/TB; similarly,
prompt diagnosis of TB in HIV-infected adults will reduce the
risk of TB transmission to their HIV-infected children. TB
control in adults more generally,89 and infection control mea-
sures, will reduce the risk of TB transmission to vulnerable chil-
dren. IPT appears similarly effective at reducing TB incidence in
HIV-infected children (around 70% reduction in incidence),71 80
and evidence suggests that use in conjunction with ART is more
protective than either intervention alone.90 Evidence for the
beneﬁt of co-trimoxazole in preventing incident TB in children
is emerging;14 since it is now recommended long-term,
co-trimoxazole prophylaxis may also help to reduce TB inci-
dence among HIV-infected children on ART. Improving nutri-
tional status among HIV-infected children may also be
beneﬁcial, as there is a high risk of TB in the context of malnu-
trition. Although individually these interventions are likely less
effective than ART, their combination can be expected to
protect the biggest number of children from developing TB.
CONCLUSIONS
Our results indicate that HIV infection is a potent risk factor for
TB in children, with a gradient of risk by indices of immunosup-
pression. ART is strongly protective against TB in children with
HIV infection, taking up to 2 years for protection to become
fully established, underscoring the importance of prompt ART
initiation.
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